This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hubert, S. K.
Right arrow Articles by Tenover, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hubert, S. K.
Right arrow Articles by Tenover, F. C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 1999, p. 3590-3593, Vol. 37, No. 11
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Glycopeptide-Intermediate Staphylococcus aureus: Evaluation of a Novel Screening Method and Results of a Survey of Selected U.S. Hospitals

Susannah K. Hubert,1 Jasmine M. Mohammed,2 Scott K. Fridkin,2 Robert P. Gaynes,2 John E. McGowan Jr.,1,* and Fred C. Tenover2

Department of Epidemiology, Rollins School of Public Health of Emory University, Atlanta, Georgia 30322,1 and Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 303332

Received 15 March 1999/Returned for modification 10 May 1999/Accepted 17 August 1999

Isolates of Staphylococcus aureus with decreased susceptibilities to glycopeptide antimicrobial agents, such as vancomycin and teicoplanin, have emerged in the United States and elsewhere. Commercially prepared brain heart infusion agar (BHIA) supplemented with 6 µg of vancomycin per ml was shown in a previous study to detect glycopeptide-intermediate S. aureus (GISA) with high sensitivity and specificity; however, this medium, when prepared in-house, occasionally showed growth of vancomycin-susceptible control organisms. This limitation could significantly impact laboratories that prepare media in-house, particularly if they wished to conduct large surveillance studies for GISA. Therefore, a pilot study to detect GISA was performed with vancomycin-containing Mueller-Hinton agar (MHA) prepared in-house in place of commercially prepared BHIA. MHA was selected for this study because this medium is widely available and well standardized. The results of the pilot study showed that supplementation of MHA with 5 µg of vancomycin per ml was both a sensitive and a specific method for screening for GISA isolates. This method was used to screen for GISA among 630 clinical isolates of methicillin-resistant S. aureus collected during 1997 from 33 U.S. hospitals. Although 14 S. aureus isolates grew on the screening agar, all were vancomycin susceptible (MICs were <= 1 µg/ml) by broth microdilution testing. Population analyses of five isolates revealed two with a subpopulation for which vancomycin MICs were 8 µg/ml. In summary, the MHA screen plate containing 5 µg of vancomycin per ml prepared in-house provides a sensitive and cost-effective method for large-scale screening for GISA for which vancomycin MICs are 8 µg/ml. However, confirmation of isolates as vancomycin resistant is critical. This study suggests that GISA was not a widespread problem in the United States in 1997.

* Corresponding author. Mailing address: Dept. of Epidemiology, Emory University, 1518 Clifton Rd. NE (Room 442GCR), Atlanta, GA 30322. Phone: (404) 727-9365. Fax: (404) 727-8737. E-mail: jmcgowa{at}sph.emory.edu.

Journal of Clinical Microbiology, November 1999, p. 3590-3593, Vol. 37, No. 11
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gould, S. W. J., Rollason, J., Hilton, A. C., Cuschieri, P., McAuliffe, L., Easmon, S. L., Fielder, M. D. (2008). UK epidemic strains of meticillin-resistant Staphylococcus aureus in clinical samples from Malta. J Med Microbiol 57: 1394-1398 [Abstract] [Full Text]  
  • Amiali, N. M., Mulvey, M. R., Berger-Bachi, B., Sedman, J., Simor, A. E., Ismail, A. A. (2008). Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 61: 95-102 [Abstract] [Full Text]  
  • Wootton, M., MacGowan, A. P., Walsh, T. R., Howe, R. A. (2007). A Multicenter Study Evaluating the Current Strategies for Isolating Staphylococcus aureus Strains with Reduced Susceptibility to Glycopeptides. J. Clin. Microbiol. 45: 329-332 [Abstract] [Full Text]  
  • French, G. L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117 [Abstract] [Full Text]  
  • Robert, J., Bismuth, R., Jarlier, V. (2006). Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 57: 506-510 [Abstract] [Full Text]  
  • Sola, C., Cortes, P., Saka, H. A., Cordoba MRSA Collaborative Study Group, , Vindel, A., Bocco, J. L. (2006). Evolution and Molecular Characterization of Methicillin-Resistant Staphylococcus aureus Epidemic and Sporadic Clones in Cordoba, Argentina. J. Clin. Microbiol. 44: 192-200 [Abstract] [Full Text]  
  • Brown, D. F. J., Edwards, D. I., Hawkey, P. M., Morrison, D., Ridgway, G. L., Towner, K. J., Wren, M. W. D., on behalf of the Joint Working Party of the Britis, (2005). Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother 56: 1000-1018 [Abstract] [Full Text]  
  • Sancak, B., Ercis, S., Menemenlioglu, D., Colakoglu, S., Hascelik, G. (2005). Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 56: 519-523 [Abstract] [Full Text]  
  • Liu, C., Chambers, H. F. (2003). Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods. Antimicrob. Agents Chemother. 47: 3040-3045 [Full Text]  
  • Kim, H. B., Park, W. B., Lee, K. D., Choi, Y. J., Park, S. W., Oh, M.-d., Kim, E.-C., Choe, K. W. (2003). Nationwide Surveillance for Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Korea. J. Clin. Microbiol. 41: 2279-2281 [Abstract] [Full Text]  
  • Decousser, J.-W., Pina, P., Picot, F., Delalande, C., Pangon, B., Courvalin, P., Allouch, P., the ColBVH study group, (2003). Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J Antimicrob Chemother 51: 1213-1222 [Abstract] [Full Text]  
  • MacKenzie, F. M., Greig, P., Morrison, D., Edwards, G., Gould, I. M. (2002). Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland. J Antimicrob Chemother 50: 689-697 [Abstract] [Full Text]  
  • Denis, O., Nonhoff, C., Byl, B., Knoop, C., Bobin-Dubreux, S., Struelens, M. J. (2002). Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother 50: 383-391 [Abstract] [Full Text]  
  • Srinivasan, A., Dick, J. D., Perl, T. M. (2002). Vancomycin Resistance in Staphylococci. Clin. Microbiol. Rev. 15: 430-438 [Abstract] [Full Text]  
  • Tallent, S. M., Bischoff, T., Climo, M., Ostrowsky, B., Wenzel, R. P., Edmond, M. B. (2002). Vancomycin Susceptibility of Oxacillin-Resistant Staphylococcus aureus Isolates Causing Nosocomial Bloodstream Infections. J. Clin. Microbiol. 40: 2249-2250 [Abstract] [Full Text]  
  • Jung, S.-I., Kiem, S., Lee, N. Y., Kim, Y.-S., Oh, W. S., Cho, H. L., Peck, K. R., Song, J.-H. (2002). One-Point Population Analysis and Effect of Osmolarity on Detection of Hetero-Vancomycin-Resistant Staphylococcus aureus. J. Clin. Microbiol. 40: 1493-1495 [Abstract] [Full Text]  
  • Ike, Y., Arakawa, Y., Ma, X., Tatewaki, K., Nagasawa, M., Tomita, H., Tanimoto, K., Fujimoto, S. (2001). Nationwide Survey Shows that Methicillin-Resistant Staphylococcus aureus Strains Heterogeneously and Intermediately Resistant to Vancomycin Are Not Disseminated throughout Japanese Hospitals. J. Clin. Microbiol. 39: 4445-4451 [Abstract] [Full Text]  
  • Wilcox, M. H., Fawley, W. (2001). Extremely low prevalence of UK Staphylococcus aureus isolates with reduced susceptibility to vancomycin. J Antimicrob Chemother 48: 144-145 [Full Text]  
  • Walsh, T. R., Bolmstrom, A., Qwarnstrom, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P., Diekema, D. (2001). Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides. J. Clin. Microbiol. 39: 2439-2444 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Berger-Bachi, B., Lew, D. P. (2001). In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 47: 163-170 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»